Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)

“The positive Phase 2a results for RAP-219 announced in September underscore both the strength of our precision neuroscience platform and the compound’s differentiated clinical potential,” said Abraham N. Ceesay, chief executive officer of Rapport. “Achieving a nearly 78% median reduction in clinical seizures and seizure freedom in nearly one in four patients positions RAP-219 with a potential best-in-class profile for the treatment of drug-resistant focal onset seizures. With a strengthened balance sheet following our recent public offering, we are in a strong financial position to execute our Phase 3 trials in focal onset seizures and continue advancing our bipolar Phase 2 trial toward topline results expected in the first half of 2027. We remain committed to disciplined execution and delivering sustained value for both patients and shareholders.”